中轴型脊柱关节炎生物制剂准入标准:超越BASDAI
基于葡萄牙风湿病登记队列594例中轴型脊柱关节炎患者,比较ASDAS与BASDAI高疾病活动度定义在筛选bDMARD治疗患者中的差异。ASDAS≥2.1较BASDAI≥4更包容,仅ASDAS达标者反应更佳,支持ASDAS≥2.1作为治疗决策标准。
要点
- ASDAS≥2.1较BASDAI≥4更包容,可多识别62%的BASDAI<4患者。
- 仅ASDAS达标者男性比例更高、HLA-B27阳性率更高、CRP更高。
- 仅ASDAS达标者bDMARD应答更优,支持ASDAS≥2.1用于治疗决策。
核心结论
- ASDAS高疾病活动度定义较BASDAI更包容,支持将ASDAS≥2.1作为axSpA患者bDMARD治疗决策标准。
研究设计与样本
- 基于葡萄牙风湿病登记(Reuma.pt)中临床诊断axSpA的患者,按ASDAS≥2.1与BASDAI≥4交叉分组比较基线特征及bDMARD治疗3和6个月应答,采用多变量回归模型。
主要发现
- 594例患者中82%同时满足BASDAI≥4和ASDAS≥2.1。
- BASDAI<4时ASDAS≥2.1的频率为62%,而BASDAI≥4时ASDAS<2.1的频率仅0.8%。
- 仅ASDAS≥2.1者较双达标者更多为男性(77% vs 51%)、HLA-B27阳性(79% vs 65%)、CRP更高(2.9 vs 2.1)。
- 359例bDMARD治疗者中各亚组应答总体重叠,但仅ASDAS达标者应答更优,如3个月ASDAS inactive disease 61% vs 25%,6个月42% vs 25%。
关键数值与推荐
- ASDAS高疾病活动度定义为≥2.1,BASDAI高疾病活动度定义为≥4。
临床怎么用
- 在axSpA患者选择bDMARD治疗时,可考虑采用ASDAS≥2.1作为高疾病活动度标准,以识别更多可能受益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare definitions of high disease activity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in selecting patients for treatment with biologic disease-modifying antirheumatic drugs (bDMARDs). METHODS: Patients from Rheumatic Diseases Portuguese Register (Reuma.pt) with a clinical diagnosis of axial spondyloarthritis (axSpA) were included. Four subgroups (cross-tabulation between ASDAS (≥2.1) and BASDAI (≥4) definitions of high disease activity) were compared regarding baseline characteristics and response to bDMARDs at 3 and 6 months estimated in multivariable regression models. RESULTS: Of the 594 patients included, the majority (82%) had both BASDAI≥4 and ASDAS ≥2.1. The frequency of ASDAS ≥2.1, if BASDAI<4 was much larger than the opposite (ie, ASDAS <2.1, if BASDAI≥4): 62% vs 0.8%. Compared to patients fulfilling both definitions, those with ASDAS ≥2.1 only were more likely to be male (77% vs 51%), human leucocyte antigen B27 positive (79% vs 65%) and have a higher C reactive protein (2.9 (SD 3.5) vs 2.1 (2.9)). Among bDMARD-treated patients (n=359), responses across subgroups were globally overlapping, except for the most 'stringent' outcomes. Patients captured only by ASDAS responded better compared to patients fulfilling both definitions (eg, ASDAS inactive disease at 3 months: 61% vs 25% and at 6 months: 42% vs 25%). CONCLUSION: The ASDAS definition of high disease activity is more inclusive than the BASDAI definition in selecting patients with axSpA for bDMARD treatment. The additionally 'captured' patients respond better and have higher likelihood of predictors thereof. These results support using ASDAS≥2.1 as a criterion for treatment decisions.
引用
- Marona J, Sepriano A, Rodrigues-Manica S, et al. Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI. RMD Open. 2020. PMID: 32144137. doi:10.1136/rmdopen-2019-001145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。